At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 123 enrolled
Drug / intervention
ND-L02-s0201 (Low Dose) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
In Brief
A Phase 2 clinical trial evaluating ND-L02-s0201 (Low Dose), ND-L02-s0201 (High Dose), and 1 other intervention for Idiopathic Pulmonary Fibrosis. Completed, enrolled 123 participants across 33 sites in 4 countries.
Detailed Summary
A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesGermany, Japan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJun 2018
Primary CompletionAug 2022
TodayJul 2026
First PostedMay 29, 2018
Enrollment StartJun 18, 2018
Primary CompletionAug 24, 2022
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 8.1 years ago
Interventions
ND-L02-s0201 (Low Dose)drug
Intravenous administration every 2 weeks
ND-L02-s0201 (High Dose)drug
Intravenous administration every 2 weeks
Other: Placeboother
Saline